I'm very surprised by the valuation that the market has applied to Biotron in this current climate.
Phase 2 trials targetting the co-infected HIV and HCV population is serious stuff.
The medical implications of such disease are enormous with serious morbidity as high as 85%.
When the re-rating comes for this stock, it will be very large.
The big question is when will the market latch on??
I'm very surprised by the valuation that the market has applied...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
